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Abstract
Under physiological conditions, intracellular and tissue levels of reactive oxygen species (ROS) are carefully
controlled and employed as fine modulators of signal transduction, gene expression and cell functional responses
(redox signaling). A significant derangement in redox homeostasis, resulting in sustained levels of oxidative stress
and related mediators, plays a role in the pathogenesis of human diseases characterized by chronic inflammation,
chronic activation of wound healing and tissue fibrogenesis, including chronic liver diseases. In this chapter major
concepts and mechanisms in redox signaling will be briefly recalled to introduce a number of selected examples
of redox-related mechanisms that can actively contribute to critical events in the natural history of a chronic liver
diseases, including induction of cell death, perpetuation of chronic inflammatory responses and fibrogenesis. A
major focus will be on redox-dependent mechanisms involved in the modulation of phenotypic responses of
activated, myofibroblast-like, hepatic stellate cells (HSC/MFs), still considered as the most relevant pro-fibrogenic
cells operating in chronic liver diseases.
Introduction
Basic concepts on oxidative stress and related reactive
mediators
Aerobic organisms use molecular oxygen (O2) as the final
electron acceptor for mitochondrial cytochrome c oxidase
that, as terminal functional element of mitochondrial
NADH dehydrogenase enzyme complex, catalyzes the four
electron reduction of oxygen [1]. During mitochondrial
oxidative phosphorylation and other electron transfer
reactions partially reduced and highly reactive O2 species
(ROS) are generated, including superoxide anion (O2
•-),
hydrogen peroxide (H2O2) and hydroxyl radical (
•OH),
that at very high levels can result in cell injury and death,
according to their properties and intracellular sources
(resumed in Figure 1). In order to survive, aerobic organ-
isms have developed evolutionary conserved mechanisms
and strategies (including antioxidant defences resumed in
Figure 2, see ref. [5] for more details) to carefully control
generation of ROS and other oxidative stress - related
mediators to maintain intracellular redox homeostasis and
to use these reactive intermediates to modulate signal
transduction, gene expression and cellular responses (i.e.,
redox signaling) [1-5]. At present, it is widely accepted
that increased and/or sustained levels of ROS and other
mediators of oxidative stress play a significant role in
atherosclerosis, diabetes, cardiovascular diseases, cancer,
neuro-degenerative diseases as well as in chronic inflam-
matory and fibrogenic diseases involving chronic activa-
tion of wound healing, including chronic liver and lung
diseases.
Generation of relevant oxidative stress mediators
In addition to major ROS like O2
•-, H2O2 and
•OH one
should remember that other reactive mediators of oxida-
tive stress are represented by end-products of lipid per-
oxidation (LPO), a complex chain reaction initiated by a
ROS or other free radicals with polyunsaturated fatty
acids of membrane phospholipids, leading to their oxida-
tive degradation, and exacerbated by the presence of
divalent metal ions [5,6]. End-products of LPO are repre-
sented by reactive aldehydes including malonyldialdehyde
(MDA) and 4-hydroxy-2,3-alkenals (HAKs) of different
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chain length as well as by F2-isoprostanes that derive
mainly by nonenzymatic peroxidation of arachidonic acid
[5,6]. Both 4-hydroxy-2,3-nonenal (HNE), the most active
HAK in biology and pathophysiology [5], as well as F2-
isoprostanes are relatively stable and lipophilic com-
pounds that can diffuse from the site of generation and
easily cross biological membranes to exert both cytotoxic
and signalling action. Their detection in biological fluids
or tissues is considered as a reliable way to evaluate “in
vivo” oxidative stress [5].
Nitric oxide (NO), a small hydrophobic molecule that
crosses cell membranes without needing channels or
receptors, is generated in living organisms by several iso-
forms of NO synthases (NOS), including one mitochon-
drial, that are able to produce NO through the conversion
of L-arginine in citrullin. NO has a role in controlling vas-
cular tone, cellular adhesion, vascular permeability and
inhibition of platelet adhesion but pathologic effects
comes from oxidation products, included in the definition
of reactive nitrogen species (RNS) such as the powerful
oxidant peroxynitrite (ONOO-) which is formed by the
rapid reaction between NO and O2
•-. When produced in
excess, peroxynitrite can oxidize any cellular constituent,
leading to disruption of cell signalling pathways and to the
induction of either necrotic or apoptotic cell death [7].
Reactions of ROS, HNE and peroxynitrite
ROS can interact with any biological macromolecule
[5,8]: a) DNA, leading to oxidative damage, strand breaks
or adduct formation (like 8-hydroxy-deoxy-Guanidine or
8-OH-dG); b) lipids, by eliciting lipid peroxidation and
subsequent degradation and fragmentation; c) proteins,
leading to oxidation of critical residues (-SH groups), for-
mation of intra-molecular disulfide bonds, thiol/disulfide
changes, formation of di-tyrosine and of protein cross
linking, or even ubiquitination and proteasomal degrada-
tion. Similar reactions have been described for ONOO-
that can, in addition, also lead to nitrosation or nitration
of proteins. HNE can exert its cytotoxic and signalling
action by forming Michael type adducts on lysine,
Figure 1 Intracellular sources and main properties of ROS. Within the cell ROS can be generated from different sources as follows: 1) as O2
•-
released at the level of complex I and III of mithocondrial electron chain reaction, with O2
•- being immediately dismutated to H2O2 by mtSOD;
2) as O2
•- following the reaction of 5-lypoxygenase on arachidonic acid, then dismutated to H2O2 by cSOD; 3) as O2
•-, then dismutated into H2O2,
following activation (i.e., ligand-receptor interaction) of NADPH oxidase in either phagocytic or non-phagocytic cells; 4) as different ROS
generated following the redox reactions catalyzed by a number of cytochromes and enzymes. Critical properties of major ROS are also briefly
summarized.
Novo and Parola Fibrogenesis & Tissue Repair 2012, 5(Suppl 1):S4
http://www.fibrogenesis.com/content/5/S1/S4
Page 2 of 8
cysteine or histidine residues as well as, by reacting with
DNA, lead to adduct formation, strand breaks and geno-
toxicity [5,6].
Redox homeostasis and redox signalling
Redox signalling is a general definition that can be used
to indicate any condition, in physiology or pathophysiol-
ogy, in which a process can be regulated or modulated
by a signal that is delivered through redox chemistry
[2-5,9]. The concept of redox homeostasis is intrinsically
simple if one translates this definition into a theoretical
condition of cells or tissues that are not exposed to
ROS. When, by any means or sources, significant levels
of ROS are generated in a biological system (i.e., altering
redox homeostasis) “redox signalling” is then represent-
ing the response or part of the response designed to
“reset” the original state of equilibrium.
Redox homeostasis
Redox homeostasis is primarily granted or controlled by
highly specialized enzymes like catalase, thioredoxins,
SODs and GPXs as well as by naturally occurring anti-
oxidants like GSH, vitamin E, b-carotene, ascorbate,
urate, and many others. The antioxidant defences (see
Figure 2) are further implemented by less specific, but
much more abundant, reactants like aminoacids, pep-
tides and proteins. In practical terms, cells in which very
low levels of ROS are generated do not suffer a signifi-
cant unbalance of pro-oxidants vs antioxidant defenses
and then do not respond by means of a redox signalling
[2-5,9,10]. Depending on the rise in intracellular levels
of ROS, the following alternatives can apply: a) low and/
or transient increase in ROS or other mediators will
lead to a time-limited shift in redox balance and redox
signalling will operate through defined redox-sensitive
signalling pathways and transcription factors to up-regu-
late genes carrying ARE (antioxidant responsive ele-
ment) sequences coding for antioxidant enzymes in
order to reset in the due time redox homeostasis; b) too
high levels of ROS and oxidants (severe oxidative stress)
can lead to irreversible damage to cell structures and
functions causing cell death; c) increased and persistent
levels of oxidative stress, not overtly able to induce cell
death, will result in a shift of the intracellular redox
state to a different, chronically deregulated state, in
which redox signalling is up-regulating different patterns
of target genes and cell responses that can sustain the
development of chronic diseases [2-5]. A note to this
didactic scenario: in a tissue undergoing chronic injury,
inflammation and wound healing the three conditions
are likely to coexist and then one can envisage an over-
all scenario in which the pathological condition is
resulting from the sum of both ROS-dependent dama-
ging effects and changes in gene expression.
Redox sensors and redox signalling
A redox sensor is a redox-sensitive specialized protein,
that is able to “sense” intracellular levels of ROS by a
Figure 2 Major antioxidant defences in mammalian cells. A brief overview of antioxidant defences is offered. Antioxidant defences have
been subdivided in those having as a major goal to display protection versus ROS and other oxidants (left panels) and in those (including both
naturally occurring and synthetic molecules) able to prevent the chain reactions of lipid peroxidation (right panels).
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redox-based mechanism affecting one or more residues/
domains within its three-dimensional structure, then
transforming the redox change into a specific “signal”
able to positively affect signalling pathways (particularly
those elicited by interaction of growth factors, cytokines,
chemokines and other peptides with their respective
receptors) and transcription of redox-sensitive genes. In
conditions of chronic liver diseases (see major events in
Figure 3) the following mechanisms and concepts are
likely to have a major role (for more details see ref.
[2-5,9,10]).
a) Reinforcement of signal transduction elicited by
peptide ligands (PDGF, VEGF, Angiotensin II, MCP-1,
TGFb1, TNF) produced in the scenario of chronic liver
diseases as a consequence of interaction with their cor-
responding membrane receptors. ROS production in
non-phagocytic cells (as hepatic myofibrobasts) can be
elicited through receptor tyrosine kinase- and Rac-
mediated activation of NADPH-oxidase or by involving
different types of receptors and signalling components
(TGFb1 operates through receptor serine/threonine
kinase and involves Smads and Src kinases).
b) ROS, generated within the cells or entering from
outside, can enhance signalling pathways by inhibiting
protein tyrosine phosphatases (PTPs) usually through
reversible oxidation of critical residues (mainly -SH
groups); prevention of de-phosphorylation can then
reinforce down-stream signal transduction of those
pathways [5,9-11].
c) Intra- and extracellular ROS can activate protein
kinases as well as MAPK cascades in the cytoplasmic
compartment. This has been described, through mild
oxidation or mild shift in the intracellular thiol/disulfide
redox state, for components belonging to the Src family
of protein tyrosine kinases (for example p59fyn and
p56lck) or JAK2, c-Jun NH2-terminal kinases (JNKs),
p38MAPK, ERK-1 and ERK-2 (the latter not in all cell
types) or some PKC isoform [2-5,9,10]. Concerning
Figure 3 Major events involved in the fibrogenic progression of chronic liver diseases. CLDs may involve different aetiological agents or
conditions able to cause persisting (i.e., chronic) parenchymal liver injury and then hepatocyte cell death (either necrosis or apoptosis). As a
result of chronic liver injury, a persistent inflammatory reaction can occur which may significantly affect the progression of the disease by either
contributing to the perpetuation of parenchymal injury or by generating a microenvironment pressure in terms of growth factor, cytokine and
other mediators that can efficiently favour tissue repair and the activation of pro-fibrogenic cells. This is the scenario that will lead to the
persistent activation of myofibroblast-like cells from different precursors. Activated MFs will contribute either to perpetuation of inflammation by
releasing pro-inflammatory mediators or to the excess synthesis and accumulation of fibrillar (rich in collagen type I and III) extracellular matrix
(ECM) components. If the aetiological agent or causal condition persists, the CLD can undergo a fibrosclerotic progression to cirrhosis and liver
failure. Since cirrhosis is characterized by formation of regenerative nodules of parenchyma surrounded and separated by fibrotic septa, this
scenario is intrinsically associated with significant changes in hepatic angio-architecture. Fibrosis itself as well as the development of hypoxic
areas have been reported to further contribute to perpetuation of liver injury.
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JNKs, two activating mechanisms have been proposed
relying on redox-activation of the upstream kinase
ASK1 or the inhibition of specific JNK-phosphatases
[12,13].
d) ROS and oxidative stress can activate defined tran-
scription factors and the best characterized examples are
NF-kB and AP-1. NF-kB, in particular, is known to be
involved in inflammatory reactions, in the control of cell
growth and in prevention of apoptosis (possibly also of
necrotic cell death) as well as in maintaining mitochon-
drial integrity and as a regulator of antioxidant activity
[14-16]. In a chronic inflammatory environment, such as
the one of CLDs, a general message is that all cytokines
leading to NF-kB activation are likely to cause intracellu-
lar generation of ROS that are then responsible for IKK
activation and IBa degradation. Once again, ROS pro-
duced within cells as a part of the response induced by
inflammatory cytokines contribute to reinforce the signal
and modulate the overall response and fate of the target
cells.
Oxidative Stress and redox signaling in chronic liver
diseases
As indicated in Figure 3, there are several events that are
relevant for fibrosclerotic progression of CLDs and that
could be considered relatively independent on the speci-
fic aetiology, including persisting hepatocyte necrotic or
apoptotic cell death, persisting inflammatory response
and chronic activation of wound healing response. Com-
prehensive reviews on the pathogenesis of CLDS and,
particularly, liver fibrogenesis and the role of hepatic
myofibroblasts (MFs) are available for the interested
reader which emphasize the role of oxidative stress
(unequivocally detected in all clinical conditions as well
as animal models of fibrogenic CLD) and related media-
tors [16-18], as well as the redox-related exacerbating
(i.e., pro-fibrogenic) role of specific factors related or not
to the aetiology (viral infection, alcohol consumption,
cholestasis, metabolic alterations in NAFLD/NASH, iron
overload, hypoxia) [5,19]. Here just a selected number of
relevant redox-dependent mechanisms and events will be
briefly resumed.
Oxidative stress and parenchymal injury
Whether natural history and progression of CLDs are con-
cerned, whatever the aetiology, persisting liver injury and
hepatocyte loss predominate and, indeed, severe oxidative
stress can be considered as a major cause for both necrotic
and apoptotic cell death of parenchymal cells [5,20-22]
either resulting from inflammatory flares (i.e., HCV or
HBV infection) through increased ROS generation by leu-
kocytes and/or following ethanol consumption, hepatic
iron overload, down-regulation of antioxidant status, to
name just a few conditions. The following major messages
should be recalled [5,20-26]: a) severe oxidative stress may
lead to both hepatocyte necrosis and apoptosis, with
necrosis mainly resulting from irreversible mitochondrial
damage and/or inactivation of executioner caspases;
b) both necrosis and apoptosis can be found on the same
section, in association with the other events of the chronic
scenario (inflammation, fibrogenesis, angiogenesis, etc.); c)
increased levels of ROS may be critical in deciding
whether the target cell may survive or die, as described for
the engagement of death receptors (DR) or Toll-like
receptors (TLR) by respective ligands and the involvement
of the critical kinase RIP (from Receptor Interacting Pro-
tein) [23-26]; d) ROS-related sustained activation of JNK
isoforms is a well characterized event leading to cell death
in several conditions; moreover, in hepatocytes NF-kB
inhibition sensitize cells to TNF-induced apoptosis by
means of JNK sustained activation [27]; e) ROS-related
mitochondrial damage is a typical example of two way-
injury since mitochondria can represent not only a source
of ROS (particularly when their integrity is deranged) but
also a target for their action in relation to cell death [26];
f) ROS are critical in mediating cell death of fatty hepato-
cytes due to excess of free fatty acids (FFAs) in the liver of
NAFLD and NASH patients; this may happen in FFAs-
related up-regulation of TNF, increased Fas ligand binding
to Fas (CD-95) or induction of endoplasmic reticulum
(ER)-stress and the so called “unfolded protein response”
(UPR) [5,28]; g) ER-stress, and then ROS, have been impli-
cated also in hepatocyte apoptosis in chronic hepatitis C
and ALD [5]; h) NO and related RNS can theoretically
promote or prevent apoptotic cell death by interfering
with either mitochondrial-dependent or -independent sig-
nalling pathways [5].
Hepatic myofibroblasts survive to oxidative stress
Human hepatic MFs can survive to ROS, HNE and other
pro-oxidants [29] and this relies on the MFs activation-
related specific “survival attitude” involving up-regulation
of Bcl2, over-activation of pro-survival pathways, including
NF-kB-related ones, and down-regulation of Bax [30,31].
Hepatic MFs can then survive to conditions of oxidative
stress usually operating in CLDs that, rather (see later), are
more likely to sustain their pro-inflammatory and pro-
fibrogenic responses.
Oxidative stress and inflammatory response
Mediators of oxidative stress, whatever the source,
aetiology or metabolic condition, are involved in the up-
regulation or modulation of the expression of pro-
inflammatory cytokines and chemokines by different
cells, (including inflammatory cells as well as HSC/MFs
or, presumably, MF-like cells, mostly through activation
of NF-kB [2-5]. In addition, the following major con-
cepts may be recalled [5]: a) ROS are involved in the
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process of phagocytosis, possibly by leading to amplifica-
tion of the stimulating signal that follows engagement of
Fc receptors on the surface of phagocytic cells; b) ROS
may have a role in apoptosis - related removal of leuko-
cytes during inflammatory responses; c) HNE as well as
other 4-hydroxy-2,3-alkenals (HAKs), have been
reported to be able to stimulate leukocyte chemotaxis at
very low concentrations; d) ROS and HNE elicit in vivo
and in vitro up-regulation of the chemokine MCP-1,
then sustaining recruitment/activation of monocytes/
macrophages and Kupffer cells as well as attracting also
HSC/MFs [5,32,33].
Oxidative stress and related mediators sustain pro-
fibrogenic action of MFs
Literature data of the last two decades have outlined that
activated, MF-like, hepatic stellate cells (HSC/MFs) and,
likely, MFs of different origin, are ideal pro-fibrogenic
targets for ROS and HNE (Figure 4) [5,16-18]. Best char-
acterized mechanisms and concepts are the following: a)
antioxidant supplementation can prevent or reduce liver
fibrosis in experimental models; b) ROS and HNE exert a
direct, paracrine pro-fibrogenic action on human HSC/
MFs by up-regulating pro-collagen type I expression,
although through different signalling pathways [5], and
the same event follows intracellular generation of ROS by
TGFb1 and leptin [34]; c) intracellular generation of ROS
occurs in HSC/MFs and hepatic MFs in association to
cytokine-receptor interactions and parallel activation of
NADPH-oxidase [5,10,35], revealing a novel putative
direct or indirect (as the case of losartan for AT-1 recep-
tor) target for therapy in CLDs; d) increased intracellular
levels of ROS, whatever the cause (cytokine-receptor inter-
action, entry from extracellular environment, increased
mitochondrial release under hypoxic conditions, following
iron overload or ER stress) is sufficient to stimulate
oriented migration in target pro-fibrogenic cells through a
biphasic mechanism [36-38]; e) intracellular generation of
ROS is emerging as a common mechanism able to med-
iate the pro-angiogenic action of PDGF-BB and leptin on
human HSC/MFs [39,40]; f) the specific mediator makes
the difference, with ROS being able to up-modulate MFs
proliferation [5] and chemotaxis [29] and HNE having no
effect on migration or even able to inhibit PDGF-depen-
dent proliferation by specifically targeting PDGF-bR
tyrosine kinase [41].
Conclusions
The final response of a target cell to oxidative stress and
related mediators may be relatively unpredictable and
Figure 4 ROS and related mediators as pro-fibrogenic stimuli for hepatic myofibroblasts. Activated hepatic stellate cells (HSC/MFs) and/or
other populations of hepatic MFs may be envisaged as putative “target” cells that modify their behavior and phenotypic responses when
exposed to the action of ROS and other oxidative stress - related reactive intermediates (for example, 4-hydroxynonenal or HNE, a major
aldehydic end-product of lipid peroxidation elicited through different mechanisms). ROS and the other reactive intermediates can be formed
following damage to hepatocytes, activation of either resident kupffer cells or macrophages recruited from peripheral circulation, release from
damaged mitochondria, generation following activation of certain cytochrome P450 isoforms (as in chronic ethanol-mediated injury or in
condition of NAFLD and NASH), to name just the most relevant options. More details can be found in the text.
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significantly affected by the steady state concentration of
reactive species, the intrinsic state of the target cell (i.e.,
activated versus quiescent), the presence of specific
growth factors and cytokines in the microenvironment
as well as of other cells able to generate ROS or HNE as
well as the concomitant generation of NO in the micro-
environment. Although severe oxidative stress may con-
tribute to the progression of CLDs by eliciting
parenchymal cell death, a significant derangement in
redox homeostasis, resulting in sustained levels of oxida-
tive stress and related mediators, is believed to play a
major role in sustaining chronic inflammatory response
as well as chronic activation of wound healing, with
hepatic MFs representing ideal target cells exhibiting
not only pro-fibrogenic but also pro-inflammatory and
pro-angiogenic properties.
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